Related Experiment Video
Updated: Jul 16, 2026
08:01
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
[Biomedical research legislation applicable since 28 August 2006]
1Service d'Urologie, CHU La Milétrie, 86000 Poitiers. merletbenoit@hotmail.com
Summary
New European legislation enhances biomedical research oversight, strengthening participant protection and ethics committee roles. This update aims to improve the quality and transparency of clinical trials across Europe.
Area of Science:
- Biomedical Research
- Clinical Trials
- Regulatory Affairs
Context:
- New legislation enacted August 28, 2006, supersedes European Directive 2001/20/EC.
- The legislation introduces significant modifications to existing biomedical research regulations.
- Focuses on reinforcing the authority of the Comité de Protection des Personnes (Ethics Committee) and governmental bodies.
Purpose:
- To summarize key aspects of the new European legislation on biomedical research.
- To aid researchers in protocol preparation under the revised regulatory framework.
- To enhance the protection of human participants in clinical research.
Summary:
- The legislation strengthens the oversight of participants and investigators.
- It mandates increased control mechanisms for enhanced subject protection.
- Publication of authorized research lists is introduced to bolster European research initiatives.
Impact:
- Improved ethical standards and subject safety in biomedical research.
- Increased transparency and accountability in clinical research.
- Facilitation of regulatory compliance for researchers conducting studies in Europe.
Related Concept Videos
01:56Ethics in Research
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:19Standards of Care II
Nurses bear specific legal responsibilities under several federal statutes, including:
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...